Patents Represented by Attorney Edward L. Mandell
  • Patent number: 5573503
    Abstract: Improved methods of ionophoretic drug delivery are described. By the intentional selection of drug(s) with specific characteristics, of ionotophoresis device, components or both permits the efficiency of drug delivery is increased.
    Type: Grant
    Filed: April 30, 1993
    Date of Patent: November 12, 1996
    Assignee: ALZA Corporation
    Inventors: Darrel F. Untereker, Joseph B. Phipps, Gary A. Lattin
  • Patent number: 5562607
    Abstract: An electrotransport system (50) includes a reusable controller (52) having a power source (60) and a separable disposable drug-containing unit (70). The controller (52) contains a switch (62) which disconnects the power source (60) from current drain when the controller (52) is uncoupled from the drug unit (70). A coupling means (74,66,105,72,64,104) physically and electrically connects together the controller (52) and the drug unit (70) such that the controller (52) provides electrical current to the drug unit (70) for electrotransport delivery of the drug to a body surface (eg, the skin) of a patient.
    Type: Grant
    Filed: January 18, 1995
    Date of Patent: October 8, 1996
    Assignee: ALZA Corporation
    Inventor: J. R. Gyory
  • Patent number: 5543098
    Abstract: An electrically powered transdermal iontophoretic delivery device (10, 20) and a method of making same is provided. The device utilizes electrode assemblies (8, 9) composed of a substantially homogenous blend of a polymeric matrix containing about 5 to 50 vol % of a conductive filler which forms a conductive network through the matrix, and up to about 50 vol % of the agent to be iontophoretically delivered through the skin. In the case of the donor electrode assembly, the agent is typically a drug and preferably a water soluble drug salt. In the case of the counter electrode assembly, the agent is typically an electrolyte salt. The homogenous blend eliminates the need for separate electrode and agent containing layers which require lamination.
    Type: Grant
    Filed: February 17, 1994
    Date of Patent: August 6, 1996
    Assignee: Alza Corporation
    Inventors: Robert M. Myers, Felix A. Landrau
  • Patent number: 5534263
    Abstract: The present invention is directed to an active agent dosage form which is useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a matrix that has on its surface two or more insoluble bands. The invention is also directed to the method for making the active agent dosage form.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: July 9, 1996
    Assignee: Alza Corporation
    Inventors: Patrick S.-L. Wong, David E. Edgren, Liang C. Dong, Vincent J. Ferrari
  • Patent number: 5533971
    Abstract: An electrotransport delivery device utilizing reservoir buffering at a select pH ranges in order to reduce skin irritation and skin resistance is provided. Cathodic reservoirs are buffered to a pH of less than about 4, preferably to a pH in the range of about 2 to 4, while anodic reservoirs are buffered to a pH above about 4, preferably to a pH in the range of about 4 to 10. Another electrotransport delivery device utilizes a potassium sensor to monitor potassium efflux from the skin. Potassium efflux above a certain predetermined level has been found to be a precursor to skin irritation/erythema. Operation of the device is modified (eg, terminated) when the predetermined potassium efflux level is sensed.
    Type: Grant
    Filed: September 3, 1993
    Date of Patent: July 9, 1996
    Assignee: Alza Corporation
    Inventor: Joseph B. Phipps
  • Patent number: 5531736
    Abstract: The present invention is directed to a fluid-imbibing dispensing device for the initially delayed delivery of an active agent to a fluid environment of use and to a method of using the dispensing device. The dispenser comprises a housing having a first wall section and a second wall section in reversibly sliding telescopic arrangement with each other, which housing maintains its integrity in the environment of use; an internal compartment surrounded and defined by the housing; at least one active agent formulation in the compartment; and expansion means and a push plate in the compartment for separating apart the first and second wall sections of the housing after exposure to the environment of use to expose the active agent formulation to the environment of use.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: July 2, 1996
    Assignee: Alza Corporation
    Inventors: Patrick S.-L. Wong, Felix Theeuwes, Steven D. Larsen, Liang C. Dong
  • Patent number: 5512293
    Abstract: This invention pertains to a sustained release delivery device for delivering a beneficial agent into the oral cavity of a patient. More particularly, the invention relates to a device comprising about 0.1% to about 20% by weight beneficial agent, about 40% to about 95% by weight ethylene vinyl acetate copolymer having a vinyl acetate content of about 4% to about 80% and about 1% to about 60% by weight polyvinyl pyrrolidone.
    Type: Grant
    Filed: December 9, 1993
    Date of Patent: April 30, 1996
    Assignee: ALZA Corporation
    Inventors: Felix A. Landrau, Patricia S. Campbell, Arthur W. Hall, Juan M. E. Harrison
  • Patent number: 5512292
    Abstract: The present invention provides compositions and methods for the transdermal administration of a contraceptively effective amount of gestodene and estrogen, such as ethinyl estradiol, in combination, together with a suitable permeation enhancer. The amount of the estrogen codelivered is kept at an about constant and contraceptively effective rate while the amount of gestogen codelivered varies depending on the phase of the menstrual cycle but remains at a contraceptively effective rate. The size of the system may also vary depending on the amount of gestogeno be delivered.
    Type: Grant
    Filed: December 21, 1994
    Date of Patent: April 30, 1996
    Assignee: ALZA Corporation
    Inventors: Robert M. Gale, Diane E. Nedberge, Linda E. Atkinson
  • Patent number: 5512299
    Abstract: A method of treating inflammatory disease of the mouth by locally delivering beclomethasone dipropionate and related compounds to the oral cavity of a patient over an extended period of time is disclosed. In one embodiment, beclomethasone dipropionate is delivered by an osmotic device (10), in another embodiment, it is delivered by an erosion controlled device (110) and in yet another embodiment, it is delivered by a diffusion controlled device (310).
    Type: Grant
    Filed: July 14, 1993
    Date of Patent: April 30, 1996
    Assignee: Alza Corporation
    Inventors: Virgil A. Place, Myriam T. Encarnacion, Patrick S. L. Wong, Juan M. E. Harrison
  • Patent number: 5508039
    Abstract: The present invention is directed to the transdermal administration of melatonin together with a suitable permeation enhancer. The invention includes a transdermal drug delivery device (10) comprising a matrix (12) adapted to be placed in melatonin- and permeation enhancer-transmitting relation with the skin site (18). The matrix (12) contains sufficient amounts of a permeation enhancer and of melatonin, in combination, to continuously administer to the skin (18) for a predetermined period of time the melatonin to provide an effective therapeutic result. The invention is also directed to a method for the transdermal administration of a therapeutically effective amount of melatonin together with a skin permeation-enhancing amount of a suitable permeation enhancer. The invention further includes methods for time- and rate-patterned transdermal delivery of melatonin to simulate the natural circadian rhythmic profile of melatonin in mammals.
    Type: Grant
    Filed: June 13, 1994
    Date of Patent: April 16, 1996
    Assignee: ALZA Corporation
    Inventors: F. Eugene Yates, Lina T. Taskovich, Su I. Yum, Nieves M. Crisologo
  • Patent number: 5503632
    Abstract: An improved cathodic iontophoresis electrode assembly (8, 38) is provided having a reducible cathodic electrode (12,22) and a drug reservoir (14, 24) containing an anionic drug. The cathodic electrode (12, 22) is separated from the drug reservoir (14, 24) by means of a layer (30) of a cation exchange material. The cation exchange material is loaded with cations which are able to react with anions produced during reduction of the electrode (12, 22) to form an electrically neutral or substantially insoluble (eg, water insoluble) compound. The cathodic electrode (12, 22) is preferably composed of silver chloride which produces chloride ions during reduction. The cation exchange material is preferably loaded with silver or copper cations which react with the chloride ions to produce a neutral and relatively insoluble metal chloride salt.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: April 2, 1996
    Assignee: Alza Corporation
    Inventor: Ronald P. Haak
  • Patent number: 5500222
    Abstract: The present invention is directed to the transdermal administration of oxybutynin together with a suitable permeation enhancer. The invention includes a transdermal drug delivery device comprising a matrix adapted to be placed in oxybutynin- and permeation enhancer-transmitting relation with the skin site. The matrix contains sufficient amounts of a permeation enhancer and of oxybutynin, in combination, to continuously administer to the skin for a predetermined period of time the oxybutynin to provide an effective therapeutic result. The invention is also directed to a method for the transdermal administration of a therapeutically effective amount of oxybutynin together with a skin permeation-enhancing amount of a suitable permeation enhancer.
    Type: Grant
    Filed: February 15, 1995
    Date of Patent: March 19, 1996
    Assignee: Alza Corporation
    Inventors: Eun S. Lee, Diane E. Nedberge, Su I. Yum
  • Patent number: 5498255
    Abstract: The present invention is directed to a fluid-imbibing dispensing device for the extended or protracted delivery of an active agent following an initially delayed startup of the delivery to a fluid environment of use.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: March 12, 1996
    Assignee: Alza Corporation
    Inventor: Patrick S.-L. Wong
  • Patent number: 5474785
    Abstract: The present invention is directed to an improvement in a delivery system, the system comprising a wall that surrounds an internal lumen or compartment which contains a thermo-responsive beneficial agent formulation, an expandable driving member and an optional density member, and having an exit opening, and wherein the improvement comprises a) a viscosity-inducing amount of an inert viscosity-inducing agent in the thermo-responsive beneficial agent composition for increasing the viscosity of the beneficial agent composition, and/or b) a pressure-inducing exit member in the exit opening in the wall for increasing the pressure inside the lumen.
    Type: Grant
    Filed: July 15, 1993
    Date of Patent: December 12, 1995
    Assignee: ALZA Corporation
    Inventors: Jeremy C. Wright, James B. Eckenhoff, Frederick H. Maruyama, John R. Peery
  • Patent number: 5464387
    Abstract: A transdermal drug delivery device (20) is provided having both an active drug reservoir (24) and a passive drug reservoir (26). Drug is actively delivered by iontophoresis from the active drug reservoir (24) by an electric field generated by a power source (21). Simultaneously, drug is delivered from passive reservoir (26) by passive (i.e., non-electrically assisted) diffusion. In one embodiment, the passive drug reservoir (26) is electrically insulated from the active drug reservoir (24). In a second embodiment, both the active and the passive drug are contained in the same reservoir (34). In the second embodiment, the active drug is ionizable while the passive drug is non-ionizable. Most preferably, the active drug is an ionizable form (i.e., a salt form) of the passive drug.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: November 7, 1995
    Assignee: Alza Corporation
    Inventors: Ronald P. Haak, Felix Theeuwes, J. Richard Gyory, Gary A. Lattin
  • Patent number: 5456679
    Abstract: Delivery devices which include a beneficial agent and an activating mechanism in separate compartments separated by a moveable partition are designed to deliver the beneficial agent in a pulsatile manner through an orifice. The pulsatile delivery is achieved by a band of resilient material which is placed over the orifice. The resilient material is sufficiently tight to substantially seal the orifice when the pressure within the device is below a threshold level while at the same time being capable of being stretched when the internal pressure exceeds the threshold.
    Type: Grant
    Filed: December 7, 1994
    Date of Patent: October 10, 1995
    Assignee: Alza Corporation
    Inventors: Stephen M. Balaban, James B. Pike, Jonathan P. Smith, Clifton A. Baile
  • Patent number: 5451407
    Abstract: The present invention is directed to the transdermal administration of methyl nicotinate and an irritating or sensitizing drug. The invention includes a transdermal drug delivery device comprising a matrix adapted to be placed in irritating/sensitizing drug- and methyl nicotinate-transmitting relation with the skin site. The matrix contains sufficient amounts of irritating/sensitizing drug and of methyl nicotinate, in combination, to continuously administer to the skin for a predetermined period of time the drug to provide an effective therapeutic result. The invention is also directed to a method for either 1) preventing or reducing the irritation caused by an irritating drug or 2) preventing or reducing sensitization from occurring, as well as reducing or eliminating pain and discomfort occurring during the elicitation phase after sensitization has already been induced.
    Type: Grant
    Filed: June 21, 1993
    Date of Patent: September 19, 1995
    Assignee: ALZA Corporation
    Inventors: Michel Cormier, Alfred Amkraut, Philip W. Ledger
  • Patent number: D362912
    Type: Grant
    Filed: December 23, 1994
    Date of Patent: October 3, 1995
    Assignee: Alza Corporation
    Inventor: Charles F. Albert
  • Patent number: D372097
    Type: Grant
    Filed: January 18, 1995
    Date of Patent: July 23, 1996
    Assignee: ALZA Corporation
    Inventors: Charles Albert, Scott J. Gilbert
  • Patent number: D372098
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: July 23, 1996
    Assignee: Alza Corporation
    Inventors: Gary A. Lattin, Tighe M. Belden, Philip C. Dretzka